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Human papillomaviruses (HPVs) infect epithelia, including the simple and the squamous epithelia of the cervix, where they can cause
cancer and precursor lesions. The molecular events leading from asymptomatic HPV infections to neoplasia are poorly understood. There is
evidence that progression is modulated by transcriptional mechanisms that control HPV gene expression. Here, we report the frequent
methylation of HPV-18 genomes in cell culture and in situ. DNA methylation is generally known to lead to transcriptional repression due to
chromatin changes. We investigated two cell lines derived from cervical cancers, namely, C4-1, which contains one HPV-18 genome, and
different clones of HeLa, with 50 HPV-18 genomes. By restriction cleavage, we detected strong methylation of the L1 gene and absence of
methylation of parts of the long control region (LCR). A 3-kb segment of the HPV-18 genomes downstream of the oncogenes was deleted in
both cell lines. Bisulfite sequencing showed that in C4-1 cells and two HeLa clones, 18 of the 19 CpG residues in the 1.2-kb terminal part of
the L1 gene were methylated, whereas a third HeLa clone had only eight methylated CpG groups, indicating changes of the methylation
pattern after the establishment of the HeLa cell line. In the same four clones, none of the 12 CpG residues that overlapped with the enhancer
and promoter was methylated. In six HPV-18 containing cancers and five smears from asymptomatic patients, most of the CpG residues in
the L1 gene were methylated. There was complete or partial methylation, respectively, of the HPV enhancer in three of the cancers, and lack
of methylation in the remaining eight samples. The promoter sequences were methylated in three of the six cancers and four of the six smears,
and unmethylated elsewhere. Our data show that epithelial cells efficiently target HPV-18 genomes for DNA methylation, which may affect
late and early gene transcription.
D 2004 Elsevier Inc. All rights reserved.Keywords: HPV-18; Methylation; Cancer
Introduction differ in their pathogenicity, as HPV-6 and 11 are mostHuman papillomavirus-18 (HPV-18) is one of the most
common HPV types involved in genital neoplasia (Bosch
et al., 1995). Together with HPV-6, 11, 16, and 31, it is
one of the model systems for transcriptional studies of
HPVs. The comparison of these viruses is desirable be-
cause they belong to three remotely related HPV groups
(HPV-6/11, HPV-16/31, and HPV-18) within the super-
group of genital HPVs (Chan et al., 1995). They also0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: hbernard@uci.edu (H.-U. Bernard).often associated with genital and laryngeal warts. HPV-
16/31 and HPV-18 give rise to cervical cancer and its
precursors, but among these lesions, HPV-16 and 31 are
preferentially associated with squamous carcinoma of the
cervix and HPV-18 with adenocarcinoma, respectively
(Andersson et al., 2001).
Only a small fraction of HPV infections progresses to
neoplastic lesions. While immunological phenomena may
determine the clearance of some HPV infections, many
infections may lead to persistence of the viral DNA in
the absence of symptoms. The mechanisms that determine
whether a persistent HPV infection remains free of
symptoms or progresses eventually to clinically detectable
neoplasia remain enigmatic. Modulation of the transcrip-
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that determine the clinical outcome of an HPV infection:
There is evidence for the stimulation of HPV oncoprotein
expression by physiological stimuli such as steroid hor-
mones (Chan et al., 1989), for major differences in HPV
transcription depending on the infected cell type (Sailaja
et al., 1999), for the differentiation state of epithelia
(O’Connor et al., 2000; Pattison et al., 1997), and for
transcriptional heterogeneity in situ in different cell pop-
ulations within individual lesions (Stoler et al., 1992).
This paper describes a part of our effort to describe
regulatory phenomena acting through specific transcrip-
tion factors or through epigenetic mechanisms that affect
the biology and pathology of genital HPVs.
The study of the viral gene expression has for many years
concentrated on the identification of cis-responsive elements
and the sequence-specific transcription factors binding these
elements (Bernard, 2002). More recently, it has become
clear that epigenetic mechanisms play a major role in
modulating the viral gene expression (Stu¨nkel and Bernard,
1999). The term ‘‘epigenetics’’ refers to regulation by
higher-order structures of the DNA, such as chromatin
conformations that either favor or repress gene expression.
The methylation of DNA is one of several mechanisms that
influences chromatin conformation (Bird, 1992). Methyla-
tion normally occurs at CpG dinucleotides, and the fact that
CpGs are present only at 20% of the statistically expected
frequency in mammalian genomes (Schorderet and Gartler,
1992) suggests adverse functional consequences of methyl-
ation as a cause for their loss during evolution. The same
applies to HPV genomes (Badal et al., 2003). With a
genome size of 7857 bp and G + C content close to 40%,
one may expect to find in the HPV-18 genome about 400
CpG sites, although it actually contains only 172.
It has been known for 20 years that the genomes of HPV-
1 and the cottontail rabbit PV can become methylated
(Burnett and Sleeman, 1984; Sugawara et al., 1983; Wett-
stein and Stevens, 1983), and that in vitro methylated HPV-
16 genomes are transcriptionally incompetent after trans-
fection into cell culture (Rosl et al., 1993). However, only
recently, we and others observed that HPV-16 DNA meth-
ylation takes regularly place in vivo in cervical samples
from asymptomatic patients, in cervical carcinoma (Badal et
al., 2003), and in cell cultures with episomal HPV-16
genomes (Kim et al., 2003). This shows that de novo
methylation regularly targets papillomavirus genomes in
somatic cells. It raises the questions of where and how
HPV genomes are recognized by the cellular DNA methyl-
ation mechanism, which enzymatic components are in-
volved in the epithelial de novo methylation, and about
the role of this transcription repression mechanism during
the normal HPV-16 life cycle and HPV-16-dependent car-
cinogenesis. The research presented in this paper addresses
the question of whether DNA methylation phenomena are,
among the genital HPVs, restricted to HPV-16, or also occur
in the remotely related type HPV-18. Our data confirm thatHPV-18 is as efficiently recognized as HPV-16. We detected
methylation preferentially in the late gene L1, but also in the
long control region (LCR), which opens the possibility that
methylation modulates HPV-18 oncogene as well as L1
transcription.Results
The restriction enzyme McrBC detects methylated HPV-18
DNA segments in several clones of HeLa and in C4-1 cells
To examine whether methylated CpG dinucleotides
(meCpGs) may occur in HPV-18 genomes, we used a
strategy successfully employed in studying HPV-16 meth-
ylation (Badal et al., 2003), namely, cleavage of the
HPV-18 genomes in certain cervical cancer-derived cell
lines by the restriction enzyme McrBC, followed by
polymerase chain reaction (PCR) amplification of seg-
ments of the viral genome and the analysis of the ampli-
cons in agarose gel electrophoresis. McrBC is an unusual
restriction enzyme, which recognizes two PumeGpGs
closely (50 bp) or even remotely (>1 kb) located relative
to one another and cleaves at unspecific positions close to
one of these meCpGs (Sutherland et al., 1992); in other
words, it recognizes on the average every other meCpG. If,
after McrBC cleavage, a DNA segment can be readily
detected after PCR amplification, one has to conclude that
in the original chromosomal DNA, the sequence was
hypomethylated. However, if the amplicon is weakened
or absent, the original DNA was hypermethylated. The
reaction is powerful in scanning larger genomic segments,
but cannot exactly quantify the amount of methylation in
each of these segments.
HeLa is a widely used cell line with about 50
genomic copies of HPV-18 recombined with cellular
sequences (Ambros and Karlic, 1987; Durst et al.,
1987; Mincheva et al., 1987; Popescu et al., 1987;
Schwarz et al., 1985). HeLa cells were among the first
cell lines ever brought into culture, derived in the middle
of the 1950s from an adenocarcinoma of the cervix of an
African American patient. Since then, HeLa cells have
been cultured separately by countless labs around the
world. During this time, they changed genetically by
chance as well as by selection, and cell lines called
‘‘HeLa’’ today diverge substantially from one another.
Here, we analyzed six different clones of HeLa (see
Materials and methods). We present the data for only
three of them as the outcome of the McrBC digestion
was the same for all six clones. Among these three, we
considered HeLa CCl2, a typical representative of the
widely used ‘‘wildtype’’ HeLa clones, D98 is a well-
known HGPRT negative mutant of HeLa, and 444 is a
clone generated during fusion studies between HeLa cells
and fibroblast. C4-1 is unrelated to HeLa, but is another
widely used cell line derived from a cervical cancer,
Fig. 2. PCR amplification and McrBC cleavage of the HPV-18 genomes in
three different HeLa clones (CCl2, D98, and 444) and the unrelated cell line
C4-1. The figure documents lack of cleavage, that is, lack of methylation of
amplicons G1–G4, deletion of amplicons G5–G7, and partial or complete
cleavage of amplicon G8, overlapping with the L1 gene. Identical data were
obtained with the HeLa clones S3, H21, and HD.
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al., 1994; Kruczek et al., 1981; Schwarz et al., 1985).
The inner circle of Fig. 1 shows a genetic map of the
HPV-18 genome, a double-stranded circular DNA with a
size of 7857 bp. The LCR is a segment of the genome
(position 7134 to 105) with most cis-responsive elements
that govern transcription and replication. Transcription of
the early genes starts counterclockwise at a promoter at
the genomic position 105 (p105) and generates multi-
cistronic transcripts of the early genes E6, E7, E1, E2,
and E5 and the late genes L2 and L1. The outer circle of
the same figure shows the division of the HPV-18
genome into eight segments that we designed as ampli-
cons, G1–G8, each with an approximate size of 1 kb.
The numbers between the amplicons indicate the 5V ends
and the arrows the orientation of the oligonucleotide
primers used for generating these amplicons.
Fig. 2 shows the McrBC digestion and PCR amplifi-
cation analysis of HeLa CCl2, HeLa D98, HeLa444, and
C4-1. We could generate the amplicons G1–G4 and G8
from all four clones but not for G5, G6, and G7. This
result was expected, as a 2- to 3-kb deletion within HPV-
18 of HeLa had been reported (Schwarz et al., 1985).
The deletion is fairly exactly defined by the borders
given in Fig. 1 (i.e. genomic position 2808 to 5918),
as experiments failed to extend the amplicons G4 and G8
even by small increments of 10–50 bp into the direction
of the deletion (data not shown). We also confirmed that
this region is deleted and not just rearranged since we
tried to generate nine different small (200–1000 bp)
amplicons throughout the G5–G7 range, without detect-
ing any HPV-18 sequences (data not shown). Strangely, aFig. 1. HPV-18, genome organization (inner circle), and position of PCR
primers (outer circle) (see also Table 1A).seemingly identical deletion of G5 to G7 occurred in C4-
1 with approximately the same borders and absence of
internal amplicons. We excluded the possibility that C4-1
cells may be a mislabeled HeLa contaminant, as sequenc-
ing of the HPV-18 variants confirmed the presence of
unrelated HPV-18 variants as published (Ong et al.,
1993).
McrBC digestion of the chromosomal DNA of these
four cell types showed no change of G1 in HeLa CCl2,
but a slight reduction in HeLa D98 and 444 and C4-1.
This may indicate, that this region with the enhancer,
promoter and replication origin of HPV-18 (Garcia-Car-
ranca et al., 1988; O’Connor et al., 1995), is not
methylated in HeLa CCl2, but that possibly some of
the 50 genomes in HeLa D98, HeLa444, and C4-1
contain meCpGs. The amplicons G2, G3, and G4, with
the early genes E6, E7, and E1, are unaltered, that is, not
methylated in all four cell lines. The amplicon G8 is
slightly reduced in HeLa CCl2, suggesting that the L1
gene in amplicon G8 is partially methylated in this clone.
The complete digestion of G8 in the other three clones
suggests heavy methylation of L1.
Six tumor samples lack major deletions of the endogenous
HPV-18 genomes
The similarity of the HPV-18 deletions in HeLa and
the unrelated C4-1 cells led to a side line question of our
methylation research, namely, the question whether this
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during carcinogenesis. To address this possibility, we
amplified the HPV-18 DNA from six tumors, two from
German (Ge18-1 and 2) and four from Scottish (Sc18-3,
2, 6, 7) patients (Ong et al., 1993). Fig. 3 shows that
there is no systematic loss of the G5-G7 segment in these
six tumors. All eight amplicons are present in the
samples Ge18-1, Sc18-3, Sc18-2, and Sc18-7, and the
missing amplicons G3 in samples Ge18-2 and G7 and
possibly G5 in sample Sc18-7 may indicate segments of
recombination between the viral and the cellular DNA.
Bisulfite sequencing of a 2022-bp L1-LCR-E6 segment of
the HPV-18 genomes in HeLa clones and C4-1
Our next objective was to establish a precise map of
the meCpGs in HeLa clones and the C4-1 cell line by
using the bisulfite sequencing technique. From this, we
hoped to learn whether there are precise correlations
between methylation patterns, genes, and cis-responsive
elements, and whether methylation may occur sporadical-
ly or continuously throughout many flanking CpG dinu-
cleotides. We decided to limit this laborious approach toFig. 3. PCR amplification of the HPV-18 genomes in six tumors, a control
experiment to confirm that loss of the amplicons G5–G7 is not a systematic
event in HPV-18-dependent carcinogenesis. Lack of other amplicons likely
indicates recombinational interruption of the HPV-18 genome in the
respective tumor.a subsegment of the HPV-18 genome, namely, the ge-
nomic position 5940 to 161, which we considered par-
ticularly informative. This segment, with a total size of
2022 bp, contains 39 CpG dinucleotides, 26 of these
potential McrBC half sites. Nineteen of these CpGs are
located in the L1 gene, which ends at position 7133.
Three are located in the 5V part of the LCR (position
7134 to an E2 binding site extending to position 7469).
Six are located in the central part of the LCR with the
enhancer, which is roughly the region between the two
E2 binding sites remote from the promoter, positions
7470 and 7821. Seven are located in the 3V part of the
LCR with the HPV-18 replication origin and promoter
(position 7822 to 104), and four downstream of p105,
within the transcript encoding the E6 gene (Fig. 4).
Fig. 4 (upper panel) summarizes our findings for three
HeLa clones and C4-1 cells. In HeLa D98, HeLa444, and
C4-1 cells, all CpGs within the L1 gene were methylated
except one at position 6871. In HeLa CCl2, only seven
CpGs were methylated in L1, no methylation being detected
at position 6039, and all methylation was discontinued after
position 6367. This explains the McrBC resistance observed
in Fig. 2. From the difference between HeLa CCl2 and
HeLa D98 and 444, one has to conclude that methylation of
chromosomally integrated HPV-18 copies can change after
integration.
Interestingly, the first CpG residue in the 5V part of
the LCR, that is, upstream of known transcriptional
regulators (position 7318), was also methylated in three
clones, whereas all CpGs downstream of this position
overlapping with the enhancer and promoter and the E6
gene were unmethylated. In the case of C4-1 cells, this
result had to be expected because the oncogenes of the
only HPV-18 genome in this cancer-derived cell line
should be transcriptionally active, that is, unmethylated.
The data suggest that in HeLa cells, all 50 HPV-18
copies are also potentially transcriptionally competent.
This outcome is discrepant from previous observations
with CaSki cells, where most of 500 HPV-16 genomes
are methylated, and only one or few remain unmethylated
and transcriptionally active (Badal et al., 2003; Van Tine
et al., 2001).
We confirmed published data (Schwarz et al., 1985) that
the HeLa clones and C4-1 cells have an active early
promoter by quantifying the E7 mRNA in a reverse tran-
scription experiment (Fig. 5). This was expected due to the
absence of methylation of the enhancer and promoter region
and shows that the methylation of the L1 gene does repress
over a long distance. We also excluded a modulation of the
early promoter by methylation of the L1 gene by treatment
of the cells with 5-azacytidin (5-azaC), a known antagonist
of DNA methylation, since we measured that 5-azaC did not
stimulate early HPV-18 transcription in any of the HeLa
clones or in C4-1 (data not shown). However, transcription
in HeLa cells may be negatively affected by a different
mechanism such as the site of genomic recombination, as
Fig. 4. Methylated CpG residues (black boxes) in a 2022-bp genomic segment of HPV-18, stretching over 1.2 kb of the L1 gene (position 5940 to 7133), the
LCR, and the 5V end of E6 (downstream of position 105). The segment contains 39 CpG dinucleotides. The top of the figure shows the overlap with genetic
elements, the vertically listed numbers the genomic positions of CpGs. White boxes: unmethylated CpGs. Grey boxes: not analyzed due to lack of material.
Fig. 5. Transcription of the HPV-18 E7 gene in four cell lines demonstrates
that methylation of the L1 gene and the 5V part of the long control region
does not repress the early promoter. (A) E7 gene of HPV-18 and the
amplicon assayed by reverse transcription PCR. (B) Reverse transcription
PCR of three HeLa cell clones and the cell line C4-1. The weaker
expression of E7 in C4-1 likely results from a gene dosage effect. No
stimulation of transcription occurred under the influence of 5-aza-C. (C)
Transcription control of a cellular gene, glyceraldehyde-3-P dehydrogenase
(GAP).
S. Badal et al. / Virology 324 (2004) 483–492 487suggested for HPV-16 genomes in CaSki cells (Van Tine et
al., 2001), as the amount of E7 mRNA was only slightly
higher in HeLa than in C4-1.
Bisulfite sequencing of a 2022-bp L1 gene-LCR segment of
the HPV-18 genomes from six cervical cancers
The central panel of Fig. 4 shows a methylation
analysis of the tumors discussed above. Some of these
data resembled the observations made with the cell lines,
others diverged. Throughout L1, most CpGs were meth-
ylated just like in the HeLa clones and in C4-1, strange-
ly, the only consistent exception being a lack of
methylation at the CpG at position 6871. Among the
remaining 18 CpGs, G18-1, G18-2, and Sc18-7 had six,
one, and two unmethylated sites. Just as in three of the
four HeLa cells, the first CpG in the 5V-LCR at position
7318 was methylated. We conclude that in cervical
cancers, just like in cancer-derived cell lines, the L1
sequences and the 5V-LCR are preferentially methylated.
The LCR and E6 sequences of these six tumors
showed a less consistent pattern. All CpGs were unme-
thylated in Ge18-1, Sc18-6, and Sc18-7. All enhancer,
promoter, and E6 sequences were methylated in Ge18-2,
Sc18-3, and Sc18-2, except three neighboring CpGs
overlapping with the enhancer of Sc18-2. We conclude
that the LCR can become methylated, although by far not
as consistently as the L1 gene. It has to be stressed that
the detection of methylated transcription units in the LCR
does not necessarily mean that all HPV-18 genomes in
these tumors were transcriptionally repressed, as exem-plified in the previously studied CaSki cell line and one
HPV-16-containing tumor (Badal et al., 2003), where
bisulfite sequencing detected a majority of methylated
and transcriptionally repressed genomes, although some
other HPV genomes remained transcriptionally active and
thereby maintained the tumor phenotype.
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HPV-18 genomes from five smears from asymptomatic
patients
We also addressed the question of whether methylation
could be found in HPV-18 genomes in cervical smears
from asymptomatic patients. Toward this, we studied five
samples from a recently published analysis of HPV-18
genome variants found in a cohort in the city of Monterrey,
Mexico (Calleja-Macias et al., 2004), Mx18-1036, 1200,
1230, 1232, and 1249. Unfortunately, due to the low
amounts of sample, we could not sequence the complete
2022-bp L1-LCR-E6 segment, but only a segment from L1
with eight CpGs and a promoter-E6 segment with 11 CpGs.
The bottom panel of Fig. 5 shows that the L1 sequences of
all four samples were completely methylated. This meth-
ylation might continue through the unsequenced part of the
3V side of the LCR, as the neighboring position 7318 was
methylated, just as in most the previously described sam-
ples. Interestingly, the enhancer of all five samples was
unmethylated, although the promoter and E6 sequences
were methylated.
It should be pointed out that all bisulfite sequencing
data analyzed directly the amplification product rather
than individual clones. As a consequence, we detected
only the predominant methylation pattern, but not micro-
heterogeneities between different HPV genomes in the
same clone or sample as recently observed (Kim et al.,
2003; our unpublished observations).Discussion
The expression ‘‘DNA methylation’’ refers to the fact that
a methyl group can be added to cytosine residues. This can
occur in any sequence constellation, but is maintained typi-
cally at CpG dinucleotides, as the palindromic nature of this
site, with methylation of the C on the upper and the lower
strand, is a prerequisite for maintenance of methylation
following replication. DNA methylation has two consequen-
ces, namely, (i) interference with the binding of some, but not
all, transcription factors (Harrington et al., 1988; Thain et al.,
1996), and (ii) being one step in a complex network of
chromatin modifications, which also includes the activities
of histone methylases and histone deacetylases (Jaenisch and
Bird, 2003). De novo DNA methylation plays a major role in
reprogramming of genetic information in early embryogen-
esis where it has been intensely studied (Jaenisch and Bird,
2003). It is enzymatically under the control of the DNA
methylases DNMT3A and B, which can also target viral
DNA that enters embryonic stem cells (Dodge et al., 2002). It
also occurs during tumorigenesis, as methylation of the
promoters of tumor suppressor genes is found in cancer as
a mechanism with similar consequences as the deletion of
tumor suppressor genes (Paulsen and Ferguson-Smith, 2001).
Very little is known about de novo methylation in somatictissue, which may occur rarely or not at all, although
DNMT3A and B could be detected in several cell types.
Under in situ conditions, the Epstein–Barr Virus (EBV) was
until recently thought to be the only virus targeted by de novo
methylation. Here, methylation may have the function to
repress the EBNA promoters, thereby reducing the availabil-
ity of immune targets during EBV-induced carcinogenesis
(Robertson, 2000).
Against this background it was a surprise when we
recently found that HPV-16 DNA is frequently methylat-
ed in cell lines and in clinical material (Badal et al.,
2003). This observation was complemented by the report
that HPV-16 DNA is frequently methylated in undiffer-
entiated cells in culture, but becomes demethylated in
differentiated cells (Kim et al., 2003). These data revived
historic reports that one can detect DNA methylation in
HPV-1 and the cottontail rabbit papillomavirus (CRPV)
(Burnett and Sleeman, 1984; Sugawara et al., 1983;
Wettstein and Stevens, 1983). From these observations,
it has to be concluded that mucosal and cutaneous
epithelia are competent to perform de novo DNA meth-
ylation, and that HPV genomes can be efficiently
detected as targets of this process. It has to remain the
objective of future research to identify, which of the
many diverse methylation patterns have transcriptional
consequences. But there is no doubt that methylation
will correlate with repression, as suggested by the study
of methylated cellular genes, by the observation that in
vitro methylated HPV DNA is transcriptionally incompe-
tent in vivo (Rosl et al., 1993), and in CaSki cells, most
of the 500 endogenous HPV-16 copies are transcription-
ally repressed correlating with their extensive methylation
(Badal et al., 2003; Van Tine et al., 2001). The phenom-
enon of HPV DNA methylation leads to many obvious
and fascinating research questions regarding the cell
populations and the enzymatic mechanisms that perform
this reaction, the recognition of HPV genomes, and the
role of methylation in the normal HPV life cycle and
during neoplasia. To study these phenomena, we decided
to firstly determine in several different HPV types the
patterns of DNA methylation. Here, we report that we
found methylation in each of 18 samples with HPV-18,
namely, in six cell lines, seven cervical cancers, and five
cervical smears from asymptomatic patients.
As a sideline of our research, we confirmed reports
that HeLa cells have about 3 kb of their genomes
deleted, and these genomic arrangements apparently did
not change over five decades of separate cloning. HeLa
was reported by one group to have HPV-18 genomes
integrated in a single chromosomal site, chromosome 8,
band q24 (Durst et al., 1987; Mincheva et al., 1987;
Schwarz et al., 1985), whereas two other groups (Ambros
and Karlic, 1987; Popescu et al., 1987) reported integra-
tion into four different chromosomal regions, one of
which confirmed as 8q24. These integration events are
apparently even more complex, as amplification of HeLa
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flanking sequences (Lazo et al., 1989). We did not follow
up on these contradictory findings, but we point out the
puzzling consequence of the latter reports with possibly
identically deleted HPV-18 genomes in four different loci.
We also report that the similar deletion in C4-1 cells was
apparently a fortuitous event, as no such deletion was
observed in six cancers. Contamination of C4-1 cells by
HeLa cells could be excluded due to the different HPV-
18 variants in the two cell lines.
In spite of the limited diagnostic power of the McrBC
analysis of clones of the six HeLa cell lines and C4-1
cells, one can conclude that methylation is absent or rare
throughout the early genes and the LCR (amplicons G1–
G4) and only detectable in the late gene L1 (G8). No
conclusions could be drawn about L2, which would have
been part of the deleted G7 segment. While McrBC is a
useful tool to scan larger genomic segments, we contin-
ued this study by bisulfite sequencing technique of a
partial genomic segment, as only few amplification
experiments were possible due to the small amounts of
DNA from clinical material.
In spite of the small number of samples analyzed by
bisulfite sequencing, our data lead us to the following
conclusions.
1. As HeLa and C4-1 cells express the E6 and E7
oncogenes, no long distance repression results from the
methylated region around L1 to the enhancer and
promoter elements located 250–600 bp 3V from the last
methylated site at position 7318.
2. Changes of the methylation status of the HPV-18 genome
can occur after clonal integration, as seen by the
differences between CCl2 and D98/444.
3. Selected sites can be resistant to methylation as
documented by site 6871, which is not only unmethy-
lated in the cell lines, but also in six tumors.
4. In many samples, methylation ends at position 7318.
This site is nearly 200 bp downstream of the 3V end of
L1, and we conclude that methylation does not strictly
correlate with the L1 gene.
5. Lack of methylation may correlate with transcription
factor binding sites since all CpGs 3V of position 7318
overlap with cis-responsive elements of the enhancer or
promoter.
6. In the cell lines and in most tumors, HPV-18 genomes are
integrated, and sequences upstream of the HPV-18
promoters are only transcribed, if they happened to
come under the control of cellular elements. This lack of
transcription, however, cannot explain the methylated
status of L1, as L1 and site 7318 are also methylated in
five smears of asymptomatic patients, likely to contain
circular HPV-18 genomes and competent to transcribe
L1. This leads to the speculation that methylation of L1
may be involved in the early-late switch of HPV-18
transcription.7. The enhancer and promoter are completely or partially
methylated in three tumors, likely indicating transcrip-
tional repression of these HPV-18 genomes. It is likely,
however, that some of the numerous HPV genomes in
these tumor cells are unmethylated and express the HPV-
18 oncogenes, as observed in CaSki cells for HPV-16.
8. In seven samples, we observed methylation of the
promoter and the E6 gene. These sequences might be
repressed by the chromatin configuration, but methyl-
ation would not affect the transcription factors directly,
as Sp1, which activates the E6 promoter, is not
affected by methylation (Harrington et al., 1988), and
E2, which is affected (Thain et al., 1996), functions in
this position as a repressor of transcription, and its
displacement would activate the promoter (Tan et al.,
1994).
Our study confirms HPV genomes as fascinating models
to study DNA methylation and makes it likely that this
mechanism has profound effects on the HPV life cycle and
carcinogenesis.Materials and methods
Origin of cell lines
Since its original cultivation in the 1950s, different cul-
tures of the HeLa have diverged substantially. We included in
this study six HeLa clones of different origins. HeLa H21
(Defilippi et al., 1987) was obtained from A.G. Porter at the
Institute of Molecular and Cell Biology (IMCB), Singapore,
who originally received it fromWalter Fiers, Rijksunivesiteit
Te Gent University. HeLa D98 was also obtained from A.G.
Porter. It is a hypoxanthine guanine phosphoribosyltransfer-
ase (HGPRT) negative, 8-azaguanin resistant mutant of HeLa
constructed more than 30 years ago (Bengtsson et al., 1975).
HeLa CCl2 (Chou et al., 1978) was received from the
American Type Culture Collection (ATCC). HeLa S3 is an
methylguanine DNA methyltransferase (MGMT)-positive
cell line (Painter and Robertson, 1959), which was obtained
from Peter Karran (Imperial Cancer Research Fund, UK), the
original source cited to be the American Type Culture
Collection. Yet another line with unknown pedigree was
obtained by one of us (H.U.B.) in 1985 at the German Cancer
Research Center in Heidelberg and maintained in our lab
since that time. HeLa444 cells were constructed during a
study of the properties of fusion cells between HeLa D98 and
fibroblasts (Srivatsan et al., 1986), and were made available
to us by Dr. E. Stanbridge (University of California Irvine).
The cell line C4-1, also derived from a cervical carci-
noma (Kruczek et al., 1981), has been reported to contain
one or few HPV-18 genomic copies (Gallego et al., 1994;
Schwarz et al., 1985) and has been made available by E.
Schwarz, Heidelberg, in 1985, and was maintained in our
Singapore laboratory since then.
logy 3Clinical specimens
Samples from cervical cancers were obtained during a
published study of the genomic diversity of HPV-18 genomes
from German and Scottish patients (Ong et al., 1993). HPV-
18 smears were identified during an epidemiological study in
Monterrey, Mexico, part of which has been published (Call-
eja-Macias et al., 2004).
Purification of DNA
DNA derived from cell lines or smears was purified with
Qiagen genomic tips following protocols suggested by the
supplier. The purification of tumor DNA has been described
(Ong et al., 1993).
McrBC cleavage
The restriction enzyme McrBC cuts close to the se-
quence purine-meC (PumeC) in the context of a second,
arbitrarily spaced PumeC (Sutherland et al., 1992). As a
consequence, McrBC recognizes pairs of PumeCpG resi-
dues, and, on the average, cleaves every other meCpG. For
digestions with McrBC (New England Biolabs), 250 ng of
chromosomal DNA was digested with 3 units of enzyme
for 1 h at 37 jC in 25 Al NE buffer 2 [50 mM NaCl, 10
mM Tris–HCl, 10 mM MgCl2, 1 mM dithiothreitol (DTT),
pH 7.9].
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PCR primers used in this study (A) for amplification of larger genomic segments
Amplicon Primer Position
A
G1 G1F 7019–7
G1R 56–3
G2 G2F 37–5
G2R 930–9
G3 G3F 876–8
G3R 1890–1
G4 G4F 1763–1
G4R 2818–7
G5 G5F 2802–2
G5R 3797–3
G6 G6F 3730–3
G6R 4784–4
G7 G7F 4721–7
G7R 5918–5
G8 G8F 5830–5
G8R 7038–7
B
Msp4–5 Msp4F 5940–5
Msp5R 6482–6
Msp6 Msp6F 6847–6
Msp6R 7186–7
Msp10 Msp10F 7282–7
Msp10R 7747–7
Msp8 Msp8F 7753–7
Msp8R 186–1PCR
Table 1A summarizes the primers for dissection of the
HPV-18 genome. PCRwas carried out in 25 Al containing 0.2
mM of each of the four dNTPs, 10 pmol primers, 2.5 Al of
buffer B supplied by the producer (Promega), 2 mM MgCl2,
and 0.75 units Taq (Promega) with 25 or 0.25 Al of C4-1 and
HeLa DNA, respectively, uncleaved or cleaved by McrBC.
The PCR started at 94 jC for 1 min followed by 35
amplification cycles (denaturation 94 jC, 10 s, annealing
58 jC, 30 s, extension 68 jC, 45 s increasing by 10 s per
cycle), final extension at 68 jC, 7 min. PCR with TaqGold
was carried out in 25 Al containing template DNA, 5 mM
dNTPs, 10 pmol primers, 2.5 Al of magnesium ion free buffer
supplied by the manufacturer, 2 mM MgCl2, and 1.25 units
AmpliTaqGold (Applied Biosystems) at 94 jC, 9 min fol-
lowed by 40 amplification cycles (denaturation at 94 jC, 10 s,
annealing 55 jC, 30 s, extension 68 jC, 45 s increasing by 10
s per cycle), final extension at 68 jC, 7 min.
Bisulfite modification, PCR, and direct sequencing
For mapping of methylated residues, DNAs were mod-
ified by the CpGenomeTm DNA modification kit of Inter-
gen Inc. or by modifications adjusted in our laboratory as
follows: 50–1000 ng sample DNA supplemented with 1 Ag
of salmon sperm DNA in a total volume of 18 Al in water
were denatured with 2 Al of 3 M NaOH and incubated at
24 (2004) 483–492(see Figs. 1–3) and (B) for amplification of bisulfite-treated DNA (Fig. 4)
Sequence
038 TTTGGTTCAGGCTGGATTGC
7 CCGACCGTTTTCGGTTACTC
6 GAGTAACCGAAAACGGTCGG
11 CCTTCTGGATCAGCCATTGT
95 TTGTGTGTCCGTGGTGTGCA
871 AGTGCTGCAACACTACTTCG
782 GCCCTGTTGCGTTACAAATG
99 ATCTTCCTCTTCCTCGTGCA
821 ACGAGGAAGAGGAAGATGCA
778 ATTGCCTGCACCTGTCCAAT
750 GATTGCGAAAACATAGCGACC
765 ATACATTACCTGCCACCTCC
740 CCTGCATTTTCTGATCCGTC
899 ACAGGCCCACACTAAACGTT
849 TTAGGGTGCAGTTACCTGAC
019 GCAATCCAGCCTGAACCAAA
960 GGTTAGTTTTTAGGTGTTGGT
461 CACACAACTACCAAATAAAACA
871 TTATTAGTTTGGTGGATATATATTG
161 AAAACATACAAACACAACAATAAATA
293 TAAAATATGTTTTGTGGTTTTGTG
721 ATAATTATACAAACCAAATATACAATT
781 TGTTTAATATTTTGTTTATTTTTAATATG
61 TATCTTACAATAAAATATTCAATTCC
S. Badal et al. / Virology 324 (2004) 483–492 49137 jC. After denaturing, 278 Al of 4.8 M sodium bisulfite
and 2 Al 100 mM hydroquinone were added and incubated
in a thermal cycler for 20 cycles each at 55 jC for 15 min
and 95 jC for 30 s. The modified DNA was desalted with
the QIAquick PCR purification protocol. The modified
DNA was desulfonated by adding 5.5 Al of 3 M NaOH,
5 Ag glycogen, and incubation at 37 jC for 15 min. The
DNA was precipitated with 5.6 Al of sodium acetate and
150 Al of 100% ethanol. The pellet was washed with 70%
ethanol and dissolved in 30–50 Al TE buffer (10 mM
Tris–HCl, pH 8, 1 mM EDTA). The reaction products
amplified with primers specific for modified HPV-18 DNA
(Table 1B) and sequenced directly. Since bisulfite-treated
DNA is partially degraded, large amplicons, it cannot be
generated, and we divided this segment in four amplicons
(5940–6482, 6847–7186, 7282–7747, 7753–186).
Reverse transcription and PCR
RNA was prepared using the QIAGEN RNA kit. One
microgram of RNA was primed with 5 pmol of oligodT
primer, topped up to 11 Al with H2O, heated at 70 jC for 10
min, and placed on ice for 5 min. A mastermix containing 2
Al of 10 New England Biolab (NEB) M-MuLV reverse
transcriptase buffer, 100mMDTT, 0.5mMof each of the four
dNTPs, 100 units NEB Reverse transcriptase enzyme, and 20
units of RNAse Inhibitor (Roche) was added to each sample
and incubated for 50 min at 42 jC. The enzyme was heat
inactivated at 70 jC for 15 min. PCR was carried out in 25
Al containing 0.2 mM of each of the four dNTPs, 10 pmol
primers, 2.5 Al of buffer B (supplied by the producer,
Promega), 2 mM MgCl2 and 0.75 units Taq polymerase
(Promega) and 1.5 Al of the cDNA preparation. The PCR
started at 94 jC for 2 min followed by 25 amplification cycles
(denaturation 94 jC, 10 s, annealing 55 jC, 30 s, extension 68
jC, 45 s), final extension at 68 jC, 7 min.Acknowledgments
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